MDSpire - Takeaway
From the Journals
Conference News

Risk Model Stratifies Heart Failure Outcomes

Biomarker score estimates risk and absolute benefit of finerenone across patient groups

Share

  • 1

    The FINEARTS-HF trial involved 6,001 patients aged 40+.

  • 2

    Finerenone was compared to placebo over a median follow-up of 32 months.

  • 3

    The biomarker-driven risk model effectively stratified patient outcomes.

  • 4

    Event rates for cardiovascular complications rose significantly with increased risk.

  • 5

    Finerenone consistently reduced hospitalization or death rates across risk groups.

  • 6

    Higher-risk patients showed greater absolute risk reduction with finerenone.

  • 7

    Some adverse effects increased with finerenone usage.

  • 8

    Study findings were presented at the ACC 75th Annual Scientific Session.

Original Source(s)

Risk Model Stratifies Heart Failure Outcomes

  • by Andrea Surnit

  • March 30, 2026

Related Content

Pregnancy-Linked SCAD More Severe

Data presented at the American College of Cardiology 75th Annual Scientific Session linked pregnancy-associated SCAD to more severe presentation and higher in-hospital major adverse cardiovascular events.

Neurofilament Levels Linked to AF Risk

Higher levels associated with stroke, death, and heart failure in long-term cohort

FDA Clears AI Guidance Tool for Mitral Repair

AI enhances real-time intraprocedural visualization and navigation.